T32-HL076130/HL/NHLBI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2007	2
2008	11
2009	12
2010	19
2011	10
2012	7
2013	4
2014	2
2022	1
2023	5
2024	1

1

Clinically relevant extracellular-matrix scaffolds for cell transplantation and vascular repair.

Tiwari-Pandey R, Toeg H, Sellke FW, Ruel M. Tiwari-Pandey R, et al. Curr Vasc Pharmacol. 2012 May;10(3):322-30. doi: 10.2174/157016112799959332. Curr Vasc Pharmacol. 2012. PMID: 22239634 Review.

2

The cardiac microvasculature in hypertension, cardiac hypertrophy and diastolic heart failure.

Hoenig MR, Bianchi C, Rosenzweig A, Sellke FW. Hoenig MR, et al. Curr Vasc Pharmacol. 2008 Oct;6(4):292-300. doi: 10.2174/157016108785909779. Curr Vasc Pharmacol. 2008. PMID: 18855717 Review.

3

Therapeutic neovascularization for coronary disease: current state and future prospects.

Lassaletta AD, Chu LM, Sellke FW. Lassaletta AD, et al. Basic Res Cardiol. 2011 Nov;106(6):897-909. doi: 10.1007/s00395-011-0200-1. Epub 2011 Jun 29. Basic Res Cardiol. 2011. PMID: 21713563 Review.

4

Resveratrol in the prevention and treatment of coronary artery disease.

Chu LM, Lassaletta AD, Robich MP, Sellke FW. Chu LM, et al. Curr Atheroscler Rep. 2011 Dec;13(6):439-46. doi: 10.1007/s11883-011-0202-3. Curr Atheroscler Rep. 2011. PMID: 21870059 Review.

5

Vascular changes after cardiac surgery: role of NOS, COX, kinases, and growth factors.

Sodha NR, Clements RT, Sellke FW. Sodha NR, et al. Front Biosci (Landmark Ed). 2009 Jan 1;14(2):689-98. doi: 10.2741/3273. Front Biosci (Landmark Ed). 2009. PMID: 19273095 Free PMC article. Review.

6

Pharmacotherapy for end-stage coronary artery disease.

Sodha NR, Chu LM, Boodhwani M, Sellke FW. Sodha NR, et al. Expert Opin Pharmacother. 2010 Feb;11(2):207-13. doi: 10.1517/14656560903439737. Expert Opin Pharmacother. 2010. PMID: 20088742 Free PMC article. Review.

7

Regenerative therapies for improving myocardial perfusion in patients with cardiovascular disease: failure to meet expectations but optimism for the future.

Sellke FW, Lassaletta AD, Robich MP, Chu LM, Ruel M. Sellke FW, et al. Curr Vasc Pharmacol. 2012 May;10(3):300-9. doi: 10.2174/157016112799959396. Curr Vasc Pharmacol. 2012. PMID: 22239632 Review.

8

Hypoxia inducible factor-1 alpha, endothelial progenitor cells, monocytes, cardiovascular risk, wound healing, cobalt and hydralazine: a unifying hypothesis.

Hoenig MR, Bianchi C, Sellke FW. Hoenig MR, et al. Curr Drug Targets. 2008 May;9(5):422-35. doi: 10.2174/138945008784221215. Curr Drug Targets. 2008. PMID: 18473772 Review.

9

Effects of canagliflozin on myocardial microvascular density, oxidative stress, and proteomic profile^☆.

Sabe SA, Xu CM, Sabra M, Harris DD, Broadwin M, Bellam KG, Banerjee D, Usheva A, Ruhul Abid M, Sellke FW. Sabe SA, et al. J Mol Cell Cardiol Plus. 2023 Dec;6:100052. doi: 10.1016/j.jmccpl.2023.100052. Epub 2023 Sep 22. J Mol Cell Cardiol Plus. 2023. PMID: 38188970 Free PMC article.

10

The future of regenerating the myocardium.

Kuraitis D, Suuronen EJ, Sellke FW, Ruel M. Kuraitis D, et al. Curr Opin Cardiol. 2010 Nov;25(6):575-82. doi: 10.1097/HCO.0b013e32833f0318. Curr Opin Cardiol. 2010. PMID: 20859204 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

65 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Results by year